03:58 AM EST, 11/06/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) reported Q3 non-GAAP earnings late Wednesday of $8.13 per diluted share, up from $6.54 a year ago.

Analysts polled by FactSet expected $5.80.

Revenue for the quarter ended Sept. 30 was $1.13 billion, up from $1.05 billion a year earlier.

Analysts surveyed by FactSet expected $1.11 billion.

For 2025, the company raised its adjusted EPS guidance to between $7.65 and $8.45 per share from $4.80 to $5.60. It narrowed its annual total revenue guidance range to between $4.18 billion and $4.28 billion from $4.15 billion to $4.30 billion.

Analysts expect adjusted EPS of $6.54 and revenue of $4.22 billion.

Shares were 1.4% lower in premarket trade Thursday.